METHOD OF PREVENTING AND TREATING THROMBOSIS
A method of preventing or treating thrombosis in a patent is disclose, wherein the method comprises administering to the patient an amount of fostamatinib or a form or metabolite thereof effective to prevent or treat the thrombosis, respectively.
1 . A method of preventing thrombosis in a subject, the method comprising administering to the subject an effective amount of R406, fostamatinib or a combination thereof effective to prevent thrombosis in the subject.
2 . The method according to claim 1 , wherein the subject has one or more risk factors for developing thrombosis.
3 . The method according to claim 1 , wherein the form of fostamatinib is fostamatinib disodium hexahydrate.
4 . A method of treating thrombosis in a subject, the method comprising administering to a patient having a thrombus an amount of a form of fostamatinib effective to treat the thrombosis in the patient.
5 . The method according to claim 4 , wherein the subject has one or more risk factors for developing thrombosis.
6 . The method according to claim 4 , wherein fostamatinib is administered in the form of fostamatinib disodium hexahydrate.
7 . The method according to claim 5 , wherein a risk factor is treatment with a TPO agonist.
8 . The method according to claim 1 , wherein the subject has received heparin.
9 . The method according to claim 8 , wherein the heparin is high molecular weight heparin.
10 . The method according to claim 1 , wherein the subject is a perioperative subject.
11 . The method according to claim 1 , wherein the R406, fostamatinib or a combination thereof is administered in conjunction with heparin.
12 . The method according to claim 11 , wherein the heparin is low molecular weight heparin.
13 . A method for treating or preventing thrombosis in a subject, comprising
identifying a subject at risk for thrombosis; and
administering to the subject an effective amount of R406, fostamatinib or a combination thereof.
14 . The method of claim 13 , wherein the subject has been treated with a TPO agonist.
15 . The method of claim 14 , wherein the subject has been treated with romiplostim, eltrombopag, IVIG, or combination thereof.
16 . The method of claim 15 , wherein the subject is a post-operative subject.
17 . The method of claim 16 , wherein the subject has been treated with unfractionated heparin.
18 . The method of claim 17 , further comprising administering low molecular weight heparin.
19 . The method of claim 13 , wherein identifying a subject at risk for thrombosis comprises in vitro detection of platelet activation.
20 . The method of claim 19 , wherein in vitro detection of platelet activation comprises a platelet aggregation assay.
21 . The method of claim 19 , wherein in vitro detection of platelet activation comprises a serotonin release assay.
22 . The method of claim 13 , wherein identifying a subject at risk for thrombosis comprises detecting heparin-PF4 antibody.
23 . The method of claim 14 , wherein identifying a subject at risk for thrombosis comprises detecting a greater than 50 percent decrease in the platelet count from baseline.